Journal
FRONTIERS IN IMMUNOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.721738
Keywords
convalescent plasma (CP); COVID; 19; SARS; CoV; 2; NK cell; T cell; CD19 CAR-T cell
Categories
Funding
- Deutsche Forschungsgemeinschaft,
Ask authors/readers for more resources
The case study described a B cell-deficient patient with COVID-19 after receiving CD19 CAR-T cell therapy. Convalescent plasma therapy correlated with virus clearance in the patient. The findings suggest that convalescent plasma therapy can activate cellular immune responses to clear SARS-CoV-2 infections, which could be important for the treatment of COVID-19 patients if further confirmed in larger clinical studies.
Here, we described the case of a B cell-deficient patient after CD19 CAR-T cell therapy for refractory B cell Non-Hodgkin Lymphoma with protracted coronavirus disease 2019 (COVID-19). For weeks, this patient only inefficiently contained the virus while convalescent plasma transfusion correlated with virus clearance. Interestingly, following convalescent plasma therapy natural killer cells matured and virus-specific T cells expanded, presumably allowing virus clearance and recovery from the disease. Our findings, thus, suggest that convalescent plasma therapy can activate cellular immune responses to clear SARS-CoV-2 infections. If confirmed in larger clinical studies, these data could be of general importance for the treatment of COVID-19 patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available